Physician profile
A Theodore Smith
NPI 1871895995
$19,414.34
in general payments reported to CMS, 2019-2025
12 companies · $364 in 2025
The $364 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,062 · 2022: $11K · 2023: $4,935 · 2024: $393 · 2025: $364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,050 · Food and Beverage: $1,535 · Travel and Lodging: $1,031 · Education: $76.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,050.00 |
| Food and Beverage | $1,534.85 |
| Travel and Lodging | $1,031.16 |
| Education | $76.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $17,820.69 | 2021-2023 | Lybalvi |
| Abbvie INC. | $446.11 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $252.25 | 2024-2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $172.00 | 2023-2024 | Caplyta |
| Neurocrine Biosciences, INC. | $155.56 | 2024 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $142.32 | 2023-2024 | Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $120.75 | 2024 | Auvelity |
| Sunovion Pharmaceuticals INC. | $100.72 | 2021 | |
| Idorsia Pharmaceuticals US INC | $78.87 | 2023 | Quviviq |
| Bioxcel Therapeutics, INC. | $74.19 | 2023 | Igalmi |
| Teva Pharmaceuticals USA, INC. | $25.48 | 2024 | Uzedy |
| Jazz Pharmaceuticals INC. | $25.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw A Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.